Please assess the completion status of the following clinical trial:

Trial Title: S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed, newly diagnosed, advanced primary non-small cell lung cancer (NSCLC) (adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or unspecified), designated as 1 of the following stages:~  * Selected stage IIIB (excluding Pancoast tumors)~    * T4 lesion due to malignant pleural effusion OR~   * Multiple lesions in a single lobe containing a T3 or T4 primary~ * Stage IV (any T, any N, M1)~ * Recurrent disease after prior surgery and/or radiotherapy~* Measurable or evaluable disease outside of prior radiation port~* No bronchoalveolar carcinoma~* No brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0-1 (for age 70 and over) (Age 70 and older with Zubrod 0-1 stratum closed to accrual as of 2/15/2003)~* Zubrod 2 (for age 18 and over)~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* SGOT/SGPT no greater than 2 times ULN if alkaline phosphatase is no greater than ULN OR~* Alkaline phosphatase no greater than 4 times ULN if SGOT/SGPT are no greater than ULN~Renal:~* Not specified~Other:~* No prior severe hypersensitivity to docetaxel or other drugs formulated with polysorbate 80~* No grade 2 or greater sensory neuropathy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior or concurrent biologic therapy for NSCLC~* No concurrent filgrastim (G-CSF)~Chemotherapy:~* No prior systemic chemotherapy for NSCLC~Endocrine therapy:~* No prior or concurrent hormonal therapy for NSCLC~Radiotherapy:~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy and recovered~* Concurrent palliative radiotherapy to small-field nonmeasurable lesions (i.e., painful bony lesions) allowed~* No other concurrent radiotherapy~Surgery:~* See Disease Characteristics~* At least 3 weeks since prior thoracic or other major surgery and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).